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ABSTRACT
PURPOSE: To evaluate the relationship between microvascular density and the expression of vascular endothelial growth factor 
(VEGF) and KIT as possible markers of angiogenic stimulus in astrocytic tumors and correlate it with histopathological grading. 
METHODS: We enrolled 99 surgical specimens of supratentorial astrocytic tumors for analysis of VEGF and KIT and subsequent 
correlation with MVD and grading. 
RESULTS: KIT and VEGF expression correlated with microvascular density (p<0.005) and both VEGF and microvascular density 
correlated with grading (p<0.005). KIT had no significant relationship with grading (p=0.657). 
CONCLUSION: KIT and VEGF constitute important pathways in the angiogenesis of astrocytomas and therefore are promising 
prognostic tools and options for therapeutic intervention. 
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Introduction
Gliomas are a heterogeneous group of primary tumors in 
the central nervous system, and comprise 40 to 50% of all brain 
tumors. The most common type of gliomas are astrocytic tumors, a 
heterogeneous group of tumors, classified by degree of malignancy 
according to World Health Organization (WHO) criteria as diffuse 
astrocytomas (grade II), anaplastic astrocytomas (grade III) or 
glioblastomas (grade IV)1. Although glioblastomas may arise de 
novo, strong evidence indicates that some glioblastomas likely 
develop from low-grade astrocytomas; these tumors may also 
follow varying pathways of biological development2. 
All of these histopathological types can recur, and can 
also be phenotypically malignant, depending on the location, 
patient’s age, health status and the extent of surgical resection. 
Though astrocytomas course of development can vary, the 
resulting outcome is frequently dismal, despite current therapeutic 
strategies. Astrocytomas infiltrate the brain diffusely, spreading 
throughout adjacent healthy tissues and recurring even after 
radical surgical resection3. 
Microvessel proliferation is one of the most important 
criteria for diagnosing malignancy in diffusely infiltrating 
astrocytic tumors4. Characterizing the molecular pathways leading 
to glioma angiogenesis and progression has clinical relevance 
because blocking molecular pathways that drive angiogenesis 
has major therapeutic implications5. Because high-grade gliomas 
are highly vascularized tumors, targeting blood vessels with 
antiangiogenic agents seems to be a promising treatment pathway6.
Although the factors controlling glioma angiogenesis are 
not fully understood, experimental data support the concept that 
angiogenesis is required for glioma growth and that the process 
is driven primarily by tumor-secreted vascular endothelial growth 
factor (VEGF)7,8. The formation of primitive blood vessels from 
progenitors like hemangioblasts and angioblasts is dependent on 
VEGF, which appears to play a major role in the angiogenesis of 
several other human tumors, such as colon and breast carcinomas9. 
The majority of anti-angiogenic therapies already 
interfere with the VEGF pathway, and the results are even more 
encouraging when anti-VEGF antibodies are combined with 
chemotherapy. Trials targeting the VEGF-signaling pathways are 
currently under development6. 
Besides VEGF, tyrosine kinase receptors, such as KIT, 
are also being investigated as having an important role in the 
cytogenetic alterations of angiogenesis process8. It is known that 
KIT, commonly present in juvenile brain tumors, also participate 
in glioma angiogenesis 
The proto-oncogene KIT encodes CD117, a 
transmembrane tyrosine kinase that has a well-established role in 
several human tumors; cellular expression of CD117 has already 
been detected by immunohistochemistry in gliomas10. In addition 
to protein expression, it has also been suggested that KIT gene 
amplification may be observed more commonly in glioblastomas 
and astrocytic tumors than in oligodendrogliomas, which 
constitute gliomas outside the astrocytic lineage11. Therefore, the 
KIT amplification seems to be linked to the astrocytic tumors. 
During angiogenesis, the KIT pathway as well as VEGF expression 
appears involved with astrocytoma growth, invasiveness and 
malignancy11,12.
The degree of tumor vascularization can be measured 
by means of the microvessel density (MVD), which serves as 
an independent prognostic marker of survival in low-grade 
fibrillary astrocytomas4,13. It has also been suggested that tumor 
angiogenesis and vascular density can be used as determinants of 
radiosensitization, of response to anti-angiogenesis drugs and as 
reliable prognostic markers13,14.
Because KIT and VEGF represent attractive possibilities 
for personalized therapy strategies, we sought to evaluate by 
immunohistochemistry the relationship between MVD, KIT and 
VEGF status and the correlation of these with histopathological 
grades in a large series of supratentorial astrocytic tumors.
Methods
This is a retrospective study based on archived slides 
and paraffin blocks with central nervous system tumors from 
the Pathology Department of the Federal University of Sao 
Paulo, Brazil. Local Ethics Committee approved this study (CEP 
1114/07). 
From 2005 to 2011, we systematically searched for all 
paraffin blocks of supratentorial astrocytomas that were archived 
before patients underwent radiotherapy. To be eligible for the 
study, tumors had to be identified as astrocytomas grades II, III 
or IV1. 
The specimens had been fixed in 10% buffered formalin 
and embedded in paraffin in preparation for light microscopy 
on hematoxilin & eosin (H&E) stained slides. Two experienced 
neuropathologists (TH, JNS) analyzed all H&E stained slides 
independently and the immunohistochemistry reactions using 
histopathological criteria outlined by the WHO to validate the 
original diagnosis, always reaching consensus.
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Immunohistochemical reactions
Immunohistochemical analysis was performed using 
4μm sections according to the standard streptavidin-biotin 
immunoperoxidase method. CD34 antigen, a transmembrane 
protein expressed on hematopoietic stem cells and the small 
vessel endothelium of various tissues, was selected to visualize the 
endothelial cells for MVD evaluation. The monoclonal antibody 
against CD34 Xm (QBEnd 10) from DAKO (Co Carpinteria, CA, 
USA), m7165, was used at a 1:100 dilution. The other monoclonal 
antibodies used included VEGF xM (C-1) from Santa Cruz (Santa 
Cruz, CA. USA), sc 7269, at a 1:100 dilution, and c-KIT/CD 117 
xR DAKO (Co Carpinteria, CA, USA), A 4502, at a 1:100 dilution. 
Deparaffinized and rehydrated slides were subjected to heat-
induced antigen retrieval for 15 minutes in a pressure cooker with 
10 mM citrate buffer (pH 6.0) at 120 °C for CD34, or immersed in 
10 mM citrate buffer (pH 6.0) during microwave heating at 700w 
for 15 minutes for VEGF and KIT. 
Evaluation of immunohistochemistry staining
Semiquantitative scores for VEGF and KIT were applied 
as following. Positive immunoreactions were categorized from 0 
to 3 according to the extent and intensity of staining: grade 0 for no 
staining; grade 1 for weak focal staining; grade 2 for strong focal 
staining; and grade 3 for strong widespread staining. 
VEGF and KIT antigen expressions were evaluated in 
the cytoplasm of neoplastic astrocytes. This graduated scale was 
adapted from Abduldrauf et al.13. For statistical analysis purposes, 
0 and 1 were classified as negative, and grades 2 and 3 were 
grouped as positive. 
Immunostained slides for CD34 were scanned field per 
field at 20x to facilitate the identification of positive reactions 
among vascular “hot spots”. Microvessel counting was performed 
using a 100x magnification in two different fields at the site 
previously defined as the “hot spots”. Images of these two fields 
were captured with a Digital Camera System DinoCapture, 
and the microvessels were manually identified using the free 
image processing and analyzing program Image Tool 3.00. If 
a discrepancy occurred in the number of vessels between the 
assessments of the two observers, the images were reassessed for 
a consensual analysis. MVD was expressed, in this study, as the 
number of vessels counted in the two hotspots.
Slides stained for CD34 were scanned at 20x for 
the identification of positive reactions. Two fields considered 
representative of vascularity were designated as vascular “hot 
spots”. Images of the two hot spots were captured with a Digital 
Camera System DinoCapture using a 100x magnification, and 
the microvessels were identified and counted using the free 
image processing and analyzing program Image Tool 3.00. If 
a discrepancy occurred in the number of vessels between the 
assessments of the two observers, the images were reassessed for 
a consensual analysis. MVD was expressed, in this study, as the 
number of vessels counted in the two fields named as hot spots.
Statistical analysis
Statistical calculations were performed using SPSS 13.0 
(SPSS Inc; Chicago, IL). In the case of a p<0.05, the result was 
considered statistically significant. Associations of MVD and KIT 
or VEGF expression were verified with the Mann-Whitney test; 
associations between MVD and tumor grade were analyzed with 
the Kruskal-Wallis test; and associations between tumor grade and 
KIT or VEGF expression were tested with Pearson chi-square tests 
(two-sided).
Results
The search retrieved material from 99 patients with 
supratentorial astrocytic tumors: 62 were men. Patients had a 
mean age of 46 years (range 20-78 years). Among the 99 patients, 
58 (58.6%) had diffuse astrocytomas (WHO grade II); 25 (25.3%) 
had anaplastic astrocytomas (WHO grade III); and 16 (16.2%) of 
the patients had glioblastomas (WHO grade IV). 
VEGF expression in grades II and III astrocytomas and 
in glioblastomas is described in Table 1. 
TABLE 1 - Mean microvascular density (MVD) and 
assessment of vascular endothelial growth factor (VEGF) and KIT 










II 24 (13-44) 25 (43.1%) 15 (25.9%)
III 33 (22-38) 16 (64%) 7 (28%)
IV 35 (28-49) 12 (75%) 6 (37.5%)
Total 29 (13-49) 53 (53.5%) 28 (28.3%)
WHO=World Health Organization1 
KIT expression was detailed in the same Table. In the 
vast majority of cases the expression for both markers, when 
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present, was diffuse. 
Correlation of MVD with KIT and VEGF expression
The MVD was significantly higher for the group of 
tumors that expressed VEGF (p<0.005). The median MVD of the 
positive group was 34 (range 21-49), whereas the negative-for-
VEGF group had a median of 23 (range 13-35), as illustrated in 
Figure 1. 
FIGURE 1 - Correlation between microvessel density (MVD) and 
vascular endothelial growth factor (VEGF) expression (Mann-Whitney 
test).
MVD was also significantly higher for the group of 
tumors that expressed KIT (p<0.005). The median MVD of the 
positive group was 34 (range 27-49), whereas the negative for the 
KIT group had a median of 25 (range 13-39), as shown in Figure 2. 
FIGURE 2 - Correlation between microvessel density (MVD) and KIT 
expression (Mann-Whitney test).
Tumor MVD was significantly associated with tumor 
grading (p<0.005), as shown in Figure 3.
 
FIGURE 3 - Correlation between microvessel density (MVD) and tumor 
grade (Kruskal Wallis test).
Correlation of tumor grading and VEGF and KIT 
expression
The grading of gliomas correlated significantly with 
VEGF expression (p<0.037). There was no association between 
KIT expression and tumor grade (p=0.657). Images of KIT and 
VEGF expression as well as microvascular density with CD34 
staining are shown in Figure 4.
FIGURE 4 - A. Low microvessel counting in a diffuse astrocytoma (grade 
II). B. High microvessel counting in an anaplastic astrocytoma (grade 
III). C. Vascular endothelial growth factor (VEGF) expression absent 
in an anaplastic astrocytoma (grade III). D. VEGF expression positive 
in a glioblastoma (grade IV). E. KIT expression absent in an anaplastic 
astrocytoma (grade III). F. KIT expression positive in an anaplastic 
astrocytoma (grade III). (A, B: CD34 staining, original magnification 
100x; C, D: VEGF staining, original magnification 200x; E, F: KIT 
staining, original magnification 200x). 
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Discussion
Low-grade astrocytomas constitute a minor group of 
all astrocytic tumors and have an inherent tendency to become 
higher grade tumors through malignant transformation. Despite 
some well-known factors related to prognosis, no unambiguous 
marker can predict astrocytoma progression15. Astrocytomas are 
a heterogeneous group of gliomas, and accurate histopathological 
diagnosis is crucial to define the prognosis of these tumors, which 
differ primarily in their abilities to grow and progress1. 
The malignant astrocytoma variants (grades III and 
IV) are the most frequently diagnosed primary brain tumors in 
adults. The migratory behavior of these malignant cells limits 
the effectiveness of surgical treatment, and the life expectancy 
of patients with glioblastomas, using current standard care, is an 
average of 14 months after diagnosis, despite the type of surgery, 
radiation and chemotherapies employed3.
Tumor microenvironments and genetic abnormalities that 
drive glioma growth, progression to malignancy and resistance to 
therapy are critical to optimize prognostic accuracy and to design 
optimal therapeutic strategies. Angiogenesis is fundamental for 
human reproduction and for wound healing, but it is also crucial 
for tumor progression, growth and metastasis. Angiogenesis is 
often present in high-grade lesions, and can be used as a prognostic 
factor. Many studies have focused on these characteristics and 
associations16,17. 
Leon et al.16 reported rich angiogenic activity in gliomas. 
Brain tumor growth was shown to depend largely on blood supply 
to provide nutrients and to remove necrotic debris from the central 
area of the neoplasm; a reciprocal relationship exists between 
the hemostatic system and tumor growth, cellular differentiation 
and metastasis. MVD is the final step of the whole process, and 
research dedicated to it allowed many authors to correlate certain 
tumors’ biological aggressiveness with vascular proliferation17. 
In our study, we found a strong relationship between vascular 
proliferation and tumor grade (p<0.005), which reinforces the 
importance of MVD status and glioma classification and prognosis 
because malignant astrocytoma progression is heralded and 
accompanied by increased angiogenesis18. 
Usually, molecular control of the angiogenic process 
entails regulating multiple steps that involve the recruitment and 
proliferation of endothelial cells, mediated by proangiogenic 
factors. Although there are many known angiogenic factors, 
vascular endothelial growth factor (VEGF) is certainly the major 
regulator in the case of gliomas and many other tumors13. Some 
reports have described the positive correlation of VEGF, vascular 
density and perfusion-weighted-imaging in gliomas19. The 
findings reported herein support this correlation because we found 
a relevant positive relation between VEGF expression and MVD 
(p<0.005). VEGF expression was also found to be significantly 
related to tumor grade (p=0.037). Yoo et al.20 reported similar 
findings in a series of 78 WHO grade II, III and IV astrocytic 
tumors. The cytokine VEGF is a multifunctional, endothelial cell-
specific mitogen and angiogenesis inducer in vivo, and, currently, 
a number of clinical trials targeting the VEGF-signaling pathways 
are being developed6. Bevacizumab, a humanized anti-VEGF 
antibody has shown promising results in exploratory phase II trials 
of recurrent GBM21. Unfortunately, the response to anti-VEGF 
therapy is usually transient, and the majority of patients eventually 
relapsed, so new data is needed to understand the mechanisms of 
tumor escape22. 
Another interesting therapeutic option is the novel 
targeted agent for KIT. Stem cell factor (SCF) is the ligand of 
the KIT receptor tyrosine kinase, which is codified by the gene 
KIT, located on chromosome 4q12 along with two other receptors 
named PDGFRA and VEGFR2, all of which are frequently 
amplified in primary glioblastomas12. SCF is up-regulated in high-
grade gliomas; it promotes angiogenesis and the survival of central 
nervous cells and is associated with a short survival23. Because 
those receptors are preferentially expressed in tumor cells, their 
inhibition poses an attractive therapeutic option that might result 
in far fewer side effects than that observed in standard treatments. 
SCF/KIT signaling pathways are involved with nervous 
system development, and interact with signal transduction 
pathways involved in carcinogenesis and cellular differentiation 
that regulate many crucial steps of tumorigenesis; their activation 
is involved with angiogenesis and gametogenesis24. Stimulation 
of KIT with SCF results in dimerization, autophsphorylation and 
the resultant activation of downstream effector proteins that have 
already been widely investigated by neuroscientists because the 
KIT gene is highly amplified in both low and high-grade gliomas25. 
Primary human gliomas express KIT and induce normal neurons 
to express KIT in brain regions infiltrated by glioma cells when 
these areas present prominent angiogenesis26. 
Sun and co-workers validated the hypothesis that KIT 
activation plays a fundamental role in glioma angiogenesis27. Its 
activation may promote these tumors’ peculiar angiogenic patterns, 
which relate to gliomas’ histopathological subtypes and vascular 
proliferation28. Our findings support this hypothesis because we 
found a positive correlation between KIT expression and MVD 
(p<0.005). Nevertheless, no correlation was found between the 
expression for KIT and the tumor grade (p=0.657). These findings 
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are consistent with those of Gomes et al.11, in that out of a series of 
179 gliomas of various grades, a positive expression for KIT was 
found in 25% (1/4) of pilocytic astrocytomas, 25% (5/20) of diffuse 
astrocytomas, 20% (1/5) of anaplastic astrocytomas and 19.5% 
(15/77) of glioblastomas and no association was found between 
KIT tumoral overexpression and patient survival. Saini et al.29 also 
found that, contrary to earlier reports, KIT expression was seen in 
32.5% (13/40) glioma cases with no association to tumor grade. 
Those findings of KIT over-expression across low/high grades in 
glioma cases are similar to ours and suggest that it may not be 
a molecular abnormality accumulated during tumor progression. 
Therefore, it is essential to elucidate whether the enhanced KIT 
expression is a cause or outcome of the glial neoplastic process29. 
Conversely, conflicting reports suggest that tumor aggressiveness 
depends on an increased expression of KIT and its activated 
form24. Cetin et al.10 studied a series of 52 glial tumors and found 
that 75% were positive for KIT, and the proportion of high-grade 
tumors was significantly greater than of low-grade tumors. 
Conclusion
The vascular endothelial growth factor and KIT are 
markers associated with microvessel density and both VEGF and 
MVD correlated with grading. KIT had no significant relationship 
with grading in astrocytic tumors. 
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